Northwest Biotherapeutics, Inc. (NASDAQ:NWBO) belonging to the Medical sector which declined -6.84% and closed its last trading session at $0.51.
The company reported its last EPS on 6/30/2016 and is expected to report its next EPS on 11/14/2016. Currently, the stock has a 1 Year Price Target of $5.
Northwest Biotherapeutics, Inc. on 6/30/2016 reported its EPS as $-0.88 with the analysts projecting the EPS of the stock as $-0.39. The company beat the analyst EPS Estimate with the difference of $-0.49. This shows a surprise factor of -125.6%.
The Company got Downgrade by Oppenheimer on 12-Mar-14 from Outperform to Perform.
Insider Trades for Northwest Biotherapeutics, Inc. show that the latest trade was made on 29 Jun 2015 where Cognate Bioservices, Inc., the Beneficial Owner of More than 10% Class completed a transaction type “Sell” in which 1118092 shares were traded at a price of $4.22.
1 analysts projected Price Targets for Northwest Biotherapeutics, Inc. The analysts believe that the company stock price could grow as high as $5. The Low Price target projection by analysts is $5 and the Mean Price Target is $5.
Northwest Biotherapeutics, Inc. (NASDAQ:NWBO) has the market capitalization of $58.74 Million. The company rocked its 52-Week High of $6.9 on Oct 5, 2015 and touched its 52-Week Low of $0.32 on Aug 29, 2016. The stock has Return on Assets (ROA) of -41.3 percent. Return on Equity (ROE) stands at 111.9% and Return on Investment (ROI) of -697.7 percent.
The stock is currently showing YTD performance of -84.2 Percent. The company has Beta Value of 1.87 and ATR value of 0.08. The Weekly and Monthly Volatility stands at 11.19% and 19.87%.
Northwest Biotherapeutics, Inc. is a biotechnology company focused on discovering, developing, and commercializing immunotherapy products that safely generate and enhance immune system responses to treat cancer.